Elite in Microvascular Decompression

Dr. Michael K. Lim

Neurosurgery
300 Pasteur Dr, 
Stanford, CA 
Offers Telehealth
Elite in Microvascular Decompression
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Lim is a Neurosurgery provider in Stanford, California. Dr. Lim is rated as an Elite provider by MediFind in Microvascular Decompression. His top areas of expertise are Trigeminal Neuralgia, Glioma, Glioblastoma, Microvascular Decompression, and Rhizotomy.

His clinical research consists of co-authoring 393 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 31 articles in the study of Microvascular Decompression.

Specialties
Neurosurgery
Licenses
Neurological Surgery in CA
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
A Phase I Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drug: MBG453
Study Phase: Phase 1
Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Biological, Other, Radiation
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
Randomized, Two-arm, Multicenter Study to Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery
Randomized, Two-arm, Multicenter Study to Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery
Enrollment Status: Completed
Publish Date: June 26, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Anti-CD137
Study Phase: Phase 1
A Pilot Study of Stereotactic Radiosurgery Combined With Nivolumab in Patients With Newly Diagnosed Melanoma Metastases in the Brain and Spine
A Pilot Study of Stereotactic Radiosurgery Combined With Nivolumab in Patients With Newly Diagnosed Melanoma Metastases in the Brain and Spine
Enrollment Status: Completed
Publish Date: November 30, 2021
Intervention Type: Radiation, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 1
A Pilot Study to Assess Feasibility of 5 Fraction Hypofractionated Stereotactic Radiosurgery Along With Standard Temozolomide as a Lymphocyte Sparing Therapy for Glioblastoma Multiforme
A Pilot Study to Assess Feasibility of 5 Fraction Hypofractionated Stereotactic Radiosurgery Along With Standard Temozolomide as a Lymphocyte Sparing Therapy for Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
Phase I Protocol to Assess Safety of Biomarker-Driven Therapy Using Selective Immune Activators in Combination With Anti-PD-1 (Nivolumab) in Patients With First Recurrence of Glioblastoma
Phase I Protocol to Assess Safety of Biomarker-Driven Therapy Using Selective Immune Activators in Combination With Anti-PD-1 (Nivolumab) in Patients With First Recurrence of Glioblastoma
Enrollment Status: Terminated
Publish Date: July 02, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases
Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Radiation
Study Phase: Phase 2
View 9 Less Clinical Trials

393 Total Publications

Dual checkpoint blockade of glioblastoma with Anti-PD-1 and Anti-LAG-3 promotes expansion of tumor-reactive T cell clones along a unique pathway of differentiation.
Dual checkpoint blockade of glioblastoma with Anti-PD-1 and Anti-LAG-3 promotes expansion of tumor-reactive T cell clones along a unique pathway of differentiation.
Journal: bioRxiv : the preprint server for biology
Published: September 18, 2025
Similar Doctors
Distinguished in Microvascular Decompression
Dr. Edward F. Chang
Neurosurgery
Distinguished in Microvascular Decompression
Dr. Edward F. Chang
Neurosurgery

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (27.6 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Chang is a Neurosurgery provider in San Francisco, California. Dr. Chang is rated as an Elite provider by MediFind in Microvascular Decompression. His top areas of expertise are Seizures, Epilepsy, Trigeminal Neuralgia, Deep Brain Stimulation, and Microvascular Decompression.

Distinguished in Microvascular Decompression
Dr. Anand Veeravagu
Neurosurgery
Distinguished in Microvascular Decompression
Dr. Anand Veeravagu
Neurosurgery

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anand Veeravagu is a Neurosurgery provider in Stanford, California. Dr. Veeravagu has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in Microvascular Decompression. His top areas of expertise are Spondylolisthesis, Spinal Stenosis, Adolescent Idiopathic Scoliosis, Laminectomy, and Spinal Fusion.

Advanced in Microvascular Decompression
Dr. Doris D. Wang
Neurosurgery
Advanced in Microvascular Decompression
Dr. Doris D. Wang
Neurosurgery

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (27.6 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Doris Wang is a Neurosurgery provider in San Francisco, California. Dr. Wang is rated as a Distinguished provider by MediFind in Microvascular Decompression. Her top areas of expertise are Parkinson's Disease, Movement Disorders, Essential Tremor, Deep Brain Stimulation, and Rhizotomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lim's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 12 Distinguished Conditions
View All 22 Advanced Conditions
View All 52 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile